Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05904769 · ClinicalTrials.gov registry record · NA
A Study of Non-invasive Measurement of Blood Glucose and Blood Pressure
A NA study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- NA
- Development phase
- 87
- Enrollment target
NCT05904769: Clinical Trial NA study, sponsored by Mayo Clinic.
NCT05904769 is a NA study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 87 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05904769, a NA study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- NA
- Development phase
- 87 participants
- Enrollment target
Study Summary
The purpose of this research is to compare blood glucose, blood pressure and electrocardiogram (ECG) readings on the LIFELEAF Smartwatch compared to standard methods of measurement.
Primary Outcome
Difference in measurement of Systolic Blood Pressure using the wrist-based PPG sensor versus invasive measurement of blood pressure measured in millimeters of mercury (mmHg).
Interventions
- DEVICE LIFELEAF Smartwatch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2024-07-31 |
| Phase | NA |
Why NCT05904769 stopped before completion
NCT05904769 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which LIFELEAF Smartwatch is the first listed.
NCT05904769 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05904769 about?
NCT05904769 is a clinical study titled "A Study of Non-invasive Measurement of Blood Glucose and Blood Pressure". The purpose of this research is to compare blood glucose, blood pressure and electrocardiogram (ECG) readings on the LIFELEAF Smartwatch compared to standard methods of measurement.
What is the current status of trial NCT05904769?
This trial is currently terminated. It is a NA study. The enrollment target is 87 participants. The study started on 2023-05-31. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT05904769?
The interventions under investigation include: LIFELEAF Smartwatch (DEVICE).
Who is sponsoring clinical trial NCT05904769?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05904769's enrollment target sits among peer trials
87 974th of 2000 higher than 1,025 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI